Key Insights

Highlights

Success Rate

67% trial completion

Treatment Research

4 treatments under study, led by Buprenorphinenaloxone

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 54/100

Termination Rate

33.3%

1 terminated out of 3 trials

Success Rate

66.7%

-19.9% vs benchmark

Late-Stage Pipeline

67%

2 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed with results

Key Signals

1 with results67% success

Data Visualizations

Phase Distribution

3Total
Not Applicable (1)
Phase 3 (2)

Trial Status

Completed2
Terminated1

Trial Success Rate

66.7%

Benchmark: 86.6%

Based on 2 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT04495673Not ApplicableTerminated

Combining Neuro-Imaging and Non-Invasive Brain Stimulation for Clinical Intervention in Opioid Use Disorder

NCT00032955Phase 3Completed

Buprenorphine/Naloxone Versus Clonidine for Inpatient Opiate Detoxification - 1

NCT00032968Phase 3Completed

Buprenorphine/Naloxone Versus Clonidine for Outpatient Opiate Detoxification - 1

Showing all 3 trials

Research Network

Common Treatments

  • Buprenorphinenaloxone2
  • Sham Transcranial Direct Current Stimulation Tdcs1
  • Cognitive Training1
  • Transcranial Direct Current Stimulation Tdcs1

Active Sponsors

  • University of California, Los Angeles2
  • University of Minnesota1
  • National Institute on Drug Abuse (NIDA)1

Top Investigators

Related Conditions

  • Heroin Dependence3
  • Substance Withdrawal Syndrome2
  • Opioidrelated Disorders1

Activity Timeline